AndhraNews.net
Home » Features » Health » Brain cancer

Brain cancer


About Brain cancer

Brain cancer is a popular type of cancer.

Brain cancer in News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Capstone Turbine Corporation of Class Action Lawsuit and Upcoming Deadline - CPST
Pomerantz LLP announces that a class action lawsuit has been filed against Capstone Turbine Corporation ("Capstone" or the "Company") (NASDAQ: CPST) and certain of its officers

ImmunoCellular Therapeutics' Andrew Gengos Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - December 17, 2015) - Los Angeles-based ImmunoCellular Therapeutics Ltd.(NYSE MKT: IMUC) is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive

Immunovaccine Announces Financial Results for Quarter Ended September 30, 2015
Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX: IMV) (OTCQX: IMMVF), a clinical-stage vaccine and immunotherapy company, today released its financial and operational results for the third quarter ended September 30, 2015.

Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
Basilea Pharmaceutica AG /Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

MD Anderson's Moon Shots Mission Grows to Confront Six More Cancer Types
HOUSTON, TX--(Marketwired - October 30, 2015) - MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.

Immunovaccine's Vaccine Candidate for Respiratory Syncytial Virus Is Well Tolerated in Volunteers in Phase 1 Clinical Trial
Immunovaccine Inc

The Grey Gala Raises More Than $260,000 to Support the National Brain Tumor Society's Mission
National Brain Tumor Society (NBTS), the largest, most influential nonprofit dedicated to the brain tumor community in the United States, hosted its inaugural Grey Gala, a national event to celebrate and honor leaders and change-makers in the field of brain tumor and cancer research, recently at the State Room in Boston, Massachusetts

IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention

Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
BONITA, CA--(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S

National Brain Tumor Society Names Leaders for Pediatric-Focused Research Effort
National Brain Tumor Society (NBTS), the largest nonprofit organization dedicated to the brain tumor community in the United States, today announced a new committee of distinguished pediatric oncologists who will advise the organization's Defeat Pediatric High-Grade Glioma Research Collaborative

Insys Therapeutics In-Licenses Cannabinoid Inhalation Technology
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that it has entered into an exclusive license agreement and partnership with U.K. based Senzer Ltd. for the development of inhaled synthetic pharmaceutical cannabinoid products including dronabinol ("THC") and cannabidiol ("CBD") using Senzer's proprietary inhalation delivery technology.

IsoRay, Inc. Reports 9% Revenue Increase for Fiscal Year 2015
RICHLAND, WA--(Marketwired - September 15, 2015) - IsoRay, Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the year and quarter ended June 30, 2015.

Gear International Funds Cannaworx Partnership With Innovative Extractions to Develop Proprietary Cannabis and Hemp Based Products
Gear International, Inc. (OTC PINK: GEAR) is pleased to announce that Cannaworx, a GEAR portfolio company, has partnered with Innovative Extractions to acquire cutting edge extraction systems in order to develop proprietary cannabis and hemp based products. The new system allows for the extraction of multiple plant materials concurrently while keeping the outputs isolated

Insys Therapeutics, Inc. Files Citizen Petition With the Drug Enforcement Administration (DEA) to Reschedule Its Synthetic Pharmaceutical Cannabidiol (CBD)
Insys Therapeutics, Inc. ("Insys" or "the Company") (NASDAQ: INSY) today announced it has filed a Citizen Petition with the Drug Enforcement Administration ("DEA") to request the agency reschedule its synthetic pharmaceutical cannabidiol ("CBD") from Schedule I to Schedule IV

PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
BONITA, CA--(Marketwired - August 17, 2015) - PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the name behind what could arguably be seen as a cure for type 1 diabetes

New Consensus Recommendations Announced for Standardized Imaging Protocol in Brain Tumor Clinical Trials
The Jumpstarting Brain Tumor Drug Development Coalition (JBTDDC) today announced a new consensus protocol for magnetic resonance imaging (MRI) in brain tumor clinical trials to help better assess if a new treatment is effective

GenSpera Provides 2nd Quarter Corporate Update
GenSpera, Inc. (OTCQB: GNSZ) on August 6, 2015, the company reported its financial results for the three and six months ended June 31, 2015, and has provided the following corporate update to its shareholders in order to highlight the Company's extensive organizational advances and clinical progress during the second quarter of 2015

NorthShore University HealthSystem Becomes First in Illinois to Install Revolutionary Neurological Operating System
EVANSTON, IL--(Marketwired - July 14, 2015) - NorthShore University HealthSystem (NorthShore) based in Evanston, Ill., has become the first in the state and only a handful in the country to utilize Synaptive Servo -- a new surgical operating system that mounts a powerful optics platform onto an automated positioning system for use with BrightMatter Guide

First Patient in Australia Treated With Revolutionary New Brainlab Radiosurgery Software
New Automatic Brain Metastases Planning software has been used for the first time in Australia at Epworth HealthCare in Richmond to deliver a tailored radiosurgery treatment to a patient with metastatic brain cancer. The patient, a 48-year-old woman with metastatic brain tumors from a primary melanoma, had dose delivered to ten metastases during her 25 minute treatment.

FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Business Wire IndiaNovocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM)

Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Potential Treatment for Gastric Cancer
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its Liposome Entrapped Paclitaxel Easy to Use ("LEP-ETU") candidate for the treatment of gastric cancer

IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.

Brain Tumor Community Pushes for Inclusion of Patient-Focused Endpoints in Future Clinical Trials
A recent workshop brought together leaders and stakeholders from the neuro-oncology, neurology, and clinical outcomes assessment fields to address the critical issue of incorporating patient-focused endpoints into future brain cancer clinical trials

Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe
Small but heading for the big time

Isoray Announces Early Success for Young Peruvian Girl Utilizing Cesium-131 in First Stereotactic Implant for Inoperable Brain Cancer
IsoRay, Inc. (NYSE MKT: ISR), announced today the excellent results achieved by a young female patient who received Cesium-131 seed via a stereotactic implant for inoperable glioblastoma brain tumor

IsoRay, Inc. Reports Fiscal Year 2014 Results
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the quarter and year ended June 30, 2014.

MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease
MedGenesis Therapeutix Inc. ("MedGenesis"), a privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, announced today that it has entered into an agreement with Pfizer Inc

IsoRay's Cesium-131 Cancer Treatment Products and Methods to Be Featured in Oral Presentations by Industry Leaders During the American Society for Radiation Oncology Convention (ASTRO)
IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO)

IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay's Cesium-131 seeds in the treatment of metastatic brain cancer.

Actelion delivers strong half year operational and financial results
Actelion Pharmaceuticals Ltd /Actelion delivers strong half year operational and financial results . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.

IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex®) which recently was FDA cleared for internal radiation therapy.

Doctor Says Brain Cancer Deaths Should Be a Wake-Up Call
Brain tumors are the second most common cause of cancer death for men ages 20 to 39. It's the fifth most common cause of cancer for women in the same age group. Those troubling statistics should be a wake-up call according to Miami Neuroscience Center Medical Director Dr. Aizik Wolf.

IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market

IsoRay, Inc. Reports Third Quarter Results
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn") cancer, announced its financial results for the quarter and nine months ended March 31, 2014.

IsoRay's Liquid Cesium-131 (Cesitrex(R)) Recieves Final Regulatory Approval for Use in GliaSite(R) Brain Cancer Treatment System
IsoRay Inc

IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic Malignancies
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of gynecologic cancer.

Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy®), for the treatment of advanced melanoma

Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer
Peregrine Pharmaceuticals, Inc

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Peregrine Pharmaceuticals, Inc

Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States

Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter of fiscal year (FY) 2014 ended October 31, 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Peregrine Pharmaceuticals Announces Upcoming Events
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the following upcoming events.

IsoRay, Inc. Reports First Quarter Results
IsoRay, Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (http://www.isoray.com/), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancers of the brain, lung, head and neck, prostate and gynecological, announced its financial results for the quarter ended September 30, 2013.

Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the presentation of data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland being held November 7-10

MagForce AG publishes Shareholder Letter
MagForce AG /MagForce AG publishes Shareholder Letter. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

MissionIR Releases Exclusive Audio Interview With CytRx Management
MissionIR today announces the online availability of its interview with CytRx Corp. (NASDAQ: CYTR) President and Chief Executive Officer Steven Kriegsman, as well as the company's Vice President of Business Development and Investor Relations David Haen. The full audio interview is available at: http://cytr.missionir.com/interview.html.

Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W

Johns Hopkins and Rutgers Medical School Now Utilizing IsoRay's Cesium-131 Sutured Seeds in Treating Metastatic Brain Cancer
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth October 21-24th at the Annual Meeting of the Congress of Neurological Surgeons

Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target
Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that participants at the International Association for the Study of Lung Cancer's (IALSC) 15th World Conference on Lung Cancer to be held October 27 - 30, 2013 in Sydney, Australia will discuss novel immunotherapy checkpoint inhibitors including Peregrine's novel target phosphatidylserine (PS)

IsoRay's Cancer Fighting Cesium-131 Seeds, Sutures and Seeded Mesh Receive High Marks With Six Abstracts Presented During (ASTRO) the American Society for Radiation Oncology Conference
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (http://www.isoray

Southeasterners Believe Brain Cancer Diagnosis Is Death Sentence as Revealed in New Survey
A new survey commissioned by the Miami Neuroscience Center (MNC) reveals that a majority of Southeasterners in the U.S. believe there is no hope for survival when brain tumors are diagnosed. The MNC survey, conducted by Toluna Global Research, randomly surveyed a cross section of men and women over the age of 25 in Florida, Georgia, and Alabama.

IsoRay, Inc. Reports Fiscal Year 2013 Results
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the year ended June 30, 2013.

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2014 ended July 31, 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research
Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced the publication of preclinical research highlighting the immune-stimulatory mechanism of action of phosphatidylserine (PS)-targeting antibodies, such as the company's lead drug candidate bavituximab

Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of fiscal year (FY) 2014 on September 9, 2013 after market and will host a conference call and webcast at 1:30 p.m

NANOBIOTIX : Half Year Results for the period ended 30 June 2013
    Small but heading for a big time

DelMar Pharmaceuticals Announces Appointment of Robert J. Toth, Jr. to Board of Directors
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to announce the appointment of Mr. Robert J. Toth, Jr. to the company's Board of Directors.

DelMar Pharmaceuticals to Accelerate Glioblastoma Clinical Trial in the United States
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the company has received a notice of allowance from the United States Food and Drug Administration (FDA) that will enable the company to accelerate the dose-escalation of its ongoing Phase I/II of VAL-083 in refractory glioblastoma multiforme (GBM) patients.

IsoRay's Cesium-131 Seeds Proves Successful for Brain Cancer Treatment as Presented by Weill Cornell and Barrow Neurological to The Society Of Neuro-Oncology
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation of clinical findings at two medical centers of the successful treatment of brain cancers and tumors using IsoRay's patented Cesium-131 (Cs-131) sutured seeds and seed sutured mesh for internal radiation therapy.

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has made significant progress in advancing its Cotara program into late-stage development through its agreement with the U.S

Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012
Peregrine Pharmaceuticals (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter of the fiscal year 2013 on December 10, 2012 after market and will host a conference call and webcast at 1:30 PM PT (4:30 PM ET)

IsoRay, Inc. Reports First Quarter Results
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gyn cancer announced its financial results for the quarter ended September 30, 2012.

New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of preclinical data showing specific localization and enhancement of anti-tumor functions of immune cells inside tumors following administration of phosphatidylserine (PS)-targeting antibodies

IsoRay's Brain and Lung Cancer Products Showcased at the American Society for Radiation Oncology (ASTRO) Convention
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 28-31, 2012 in Boston, Massachusetts at the Boston Convention and Exhibition Center

Peregrine Pharmaceuticals Provides Update on Corporate Activities
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided a company update on financing activities, its contract manufacturing business and upcoming potential clinical milestones.

IsoRay, Inc. Reports Fiscal Year 2012 Results
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the quarter and year ended June 30, 2012.

Peregrine Pharmaceuticals Announces New Location of Annual Meeting of Stockholders
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has changed the location of its Annual Meeting of Stockholders to be held on October 18, 2012 at 10:00 am Pacific Daylight Time as follows:

Peregrine Pharmaceuticals Announces That It Has Discovered Major Discrepancies in Treatment Group Coding by an Independent Third-Party Vendor Responsible for Distribution of Blinded Investigational Product Used in Its Bavituximab Phase II Second-Line Non-Small Cell Lung Cancer Trial

Peregrine to Participate in Credit Suisse 2012 Small & Mid Cap Conference on September 21, 2012
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that its management team will be meeting with investors to review its portfolio of novel drug candidates and the recent positive clinical data from the company's Phase II trial in second-line non-small cell lung cancer, as part of the 3rd Annual Credit Suisse 2012 Small & Mid Cap Conference

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the first quarter ended July 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms

Peregrine to Report First Quarter Fiscal Year 2013 Financial Results Before Market on September 10, 2012
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of the fiscal year 2013 on September 10, 2012 before market and will host a conference call and webcast at 8:00 AM PDT (11:00 AM EDT)

Data From Peregrine's Phase II Bavituximab Second-Line Lung Cancer Trial to Be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
Peregrine Pharmaceuticals, Inc

A*STAR Scientists Discover Potential Drug for Deadly Brain Cancer
A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults - glioblastoma multiforme(1). The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour

Peregrine Pharmaceuticals Secures $30 Million Loan Facility
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that it has secured a $30 million term loan from Oxford Finance, which was the lead lender, MidCap Financial, and Silicon Valley Bank. Under the loan facility, the company received initial funding of $15 million and has an option to receive an additional $15 million.

Peregrine to Present at Stifel Nicolaus Healthcare Conference September 5, 2012 at 2:40 PM EDT
Peregrine Pharmaceuticals, Inc

Peregrine to Present at Wedbush Securities Life Sciences Management Access Conference on August 15, 2012 at 10:55 AM EDT
Peregrine Pharmaceuticals, Inc

Peregrine Provides Update on HCV Clinical Program
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV)

Marijuana, Inc. (HEMP.PK) Supports "The Cash Hyde Fund for Cancer Awareness" as Its TV Division Films Recent Fund Raising Event
Marijuana, Inc. (PINKSHEETS: HEMP) is proud to announce the first event covered by MarijuanaIncTV LIVE as its film crew documented The Art of Mary Jane Magazine/Cash Hyde Foundation well attended Fundraiser held at actor and filmmaker Sean Cook's Bel Air, California estate, on Saturday, Dec. 10, 2011.

Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and provided an update on its advancing clinical pipeline and other corporate developments.

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced preliminary results from a randomized Phase II trial showing a 50% improvement in overall tumor response rates (ORR) in non-small cell lung cancer (NSCLC) patients

Peregrine to Report Second Quarter Fiscal Year 2012 Financial Results After Market on December 12, 2011
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the second quarter of the fiscal year 2012 on December 12, 2011 after market and will host a conference call and webcast at 1:30 PM PST (4:30 PM EST)

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 23

IMG Mourns the Passing of Beloved Chairman and CEO Ted Forstmann
It is with great sadness that IMG Worldwide announces the passing of its Chairman and Chief Executive Officer, Theodore J. ("Ted") Forstmann. Mr. Forstmann passed away today after a courageous battle against brain cancer.

J.Lo felt she's gonna die after finding lump on daughter's head
Jennifer Lopez has revealed how she got panicked after she discovered a lump on daughter Emme's head when she was just days old.

Padma Laxmi's ex beau Theodore Forstmann dies at 71
Theodore 'Teddy' Forstmann, a veteran business leader and philanthropist who had been romantically linked to Padma Lakshmi, died on Sunday. He was 71.

Walter Mondale's daughter kept secret diary about her affair with Bill Clinton
Eleanor Mondale, the daughter of former US vice president Walter Mondale who died of brain cancer last week, is said to have kept a secret diary about her alleged affair with Bill Clinton.

Comment on this story

Share